News Relief for AZ as Truqap hits the spot in prostate cancer After a disappointing result with Truqap in triple-negative breast cancer, AstraZeneca chalks up a win in prostate cancer
News Roche finally drops curtain on AKT drug ipatasertib In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update
News Ambros' $125m for pain disorder drug, and other financings Our latest crop of biofinancings has nine-figure rounds for Ambros, Atavistik, Orum, and Addition, with Link Cell and Aeovian also raising new funds.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
